Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RenovoRx ( (RNXT) ) has provided an update.
On June 24, 2025, RenovoRx, Inc. held its annual meeting where stockholders voted on several key proposals. The election of directors resulted in the reappointment of six individuals for a one-year term. Additionally, amendments to the company’s 2021 Omnibus Equity Incentive Plan were approved, increasing the shares reserved for issuance and adjusting the plan’s evergreen provision. The appointment of Frank, Rimerman + Co. LLP as the independent auditor for 2025 was also ratified.
The most recent analyst rating on (RNXT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on RenovoRx stock, see the RNXT Stock Forecast page.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
RenovoRx’s overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company’s valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
Average Trading Volume: 159,473
Technical Sentiment Signal: Strong Buy
Current Market Cap: $51.57M
For an in-depth examination of RNXT stock, go to TipRanks’ Overview page.